Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care

Similar documents
DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #408: Opioid Therapy Follow-up Evaluation National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #293: Parkinson s Disease: Rehabilitative Therapy Options National Quality Strategy Domain: Communication and Care Coordination

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Quality ID #435: Quality of Life Assessment For Patients With Primary Headache Disorders National Quality Strategy Domain: Effective Clinical Care

Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care

Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

DESCRIPTION: Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

NUMERATOR: Female patients or caregivers counseled at least once a year about how epilepsy and its treatment may affect contraception OR pregnancy

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Measure #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Intermediate Outcome

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Measure #279: Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy National Quality Strategy Domain: Effective Clinical Care

Quality ID #351: Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation National Quality Strategy Domain: Patient Safety

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination

Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

Measure #403: Adult Kidney Disease: Referral to Hospice National Quality Strategy Domain: Patient and Caregiver-Centered Experience and Outcomes

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

Quality ID #329: Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

DESCRIPTION: Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months

Quality ID #187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy National Quality Strategy Domain: Effective Clinical Care

Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #342: Pain Brought Under Control Within 48 Hours National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period

Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Patient Reported Outcome High Priority

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Quality ID# 406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients National Quality Strategy Domain: Effective Clinical Care

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Measure #404: Anesthesiology Smoking Abstinence National Quality Strategy Domain: Effective Clinical Care

Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

Quality ID #443: Non-Recommended Cervical Cancer Screening in Adolescent Females National Quality Strategy Domain: Patient Safety

Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #166 (NQF 0131): Coronary Artery Bypass Graft (CABG): Stroke- National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Transcription:

Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: All patients 18 and older prescribed opiates for longer than six weeks duration evaluated for risk of opioid misuse using a brief validated instrument (e.g. Opioid Risk Tool, SOAPP-R) or patient interview documented at least once during Opioid Therapy in the medical record INSTRUCTIONS: This measure is to be submitted once per performance period for all patients being prescribed opioids for duration longer than six weeks during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission: The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data. DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration Denominator Criteria (Eligible Cases): Patients aged 18 years on date of encounter AND Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350 WITHOUT Telehealth Modifier: GQ, GT, 95, POS 02 AND Patients prescribed opiates for longer than six weeks: G9583 NUMERATOR: Patients evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., Opioid Risk Tool, Opioid Assessment for Patients with Pain, revised (SOAPP-R)) or patient interview at least once during opioid therapy OR Numerator Options: Performance Met: Performance Not Met: Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., Opioid Risk Tool, SOAPP-R) or patient interviewed at least once during opioid therapy (G9584) Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., Opioid Risk Page 1 of 5

Tool, SOAPP-R) or patient not interviewed at least once during opioid therapy (G9585) RATIONALE: A thorough history and physical examination, including an assessment of psychosocial factors and family history, is essential for adequate risk stratification. Implicit in the recommendation to conduct a comprehensive benefit-to-harm analysis is the recognition that an opioid trial may not be appropriate. Clinicians should obtain appropriate diagnostic tests to evaluate the underlying pain condition, and should consider whether the pain condition may be treated more effectively with nonopioid therapy rather than with COT. CLINICAL RECOMMENDATION STATEMENTS: Before initiating COT, clinicians should conduct a history, physical examination and appropriate testing, including an assessment of risk of substance abuse, misuse, or addiction (strong recommendation, low-quality evidence). Clinicians may consider a trial of COT as an option if chronic noncancer pain (CNCP) is moderate or severe, pain is having an adverse impact on function or quality of life, and potential therapeutic benefits outweigh or are likely to outweigh potential harms (strong recommendation, low-quality evidence). A benefit-to-harm evaluation including a history, physical examination, and appropriate diagnostic testing, should be performed and documented before and on an ongoing basis during COT (strong recommendation, low-quality evidence) (p. 115). Tools that appear to have good content, face, and construct validity include the Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1, the revised SOAPP (SOAPP-R), the Opioid Risk Tool (ORT), and the Diagnosis, Intractability, Risk, Efficacy (DIRE) instrument (p.116). COPYRIGHT: 2015 American Academy of Neurology Institute All rights reserved. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary coding sets should obtain all necessary licenses from the owners of these code sets. The AAN and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT ) or other coding contained in the specifications. CPT is a registered trademark of the American Medical Association. Page 2 of 5

Page 3 of 5

2018 Registry Flow for Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry data submission. 1. Start with Denominator 2. Check Patient Age: a. If the Age is greater than or equal to 18 years of age on Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing. b. If the Age is greater than or equal to 18 years of age on Date of Service and equals Yes during the measurement period, proceed to check Encounter Performed. 3. Check Encounter Performed: a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier. 4. Check Telehealth Modifier: a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing. b. If Telehealth Modifier equals No, proceed to Patients Prescribed Opiates For Longer Than Six weeks. 5. Check Patients Prescribed Opiates For Longer Than Six weeks: a. If Patients Prescribed Opiates For Longer Than Six weeks equals No, do not include in Eligible Patient Population. Stop Processing. b. If Patients Prescribed Opiates For Longer Than Six weeks equals Yes, include in Eligible Patient Population. 6. Denominator Population: a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation. 7. Start Numerator 8. Check Patients Evaluated For Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy: a. If Patients Evaluated For Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation. Page 4 of 5

c. If Patients Evaluated For Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy equals No, proceed to Patients Not Evaluated for Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy. 9. Check Patients Not Evaluated for Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy: a. If Patients Not Evaluated for Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy equals Yes, include in Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 patients in the Sample Calculation. c. If Patients Not Evaluated for Risk of Misuse of Opiates by Using a Brief Validated Instrument or Patient Interviewed at Least Once During Opioid Therapy equals No, proceed to Data Completeness Not Met. 10. Check Data Completeness Not Met: a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation. SAMPLE CALCULATIONS: Data Completeness= Performance Met (a=40 patients) + Performance Not Met (c=30 patients) = 70 patients = 87.50% Eligible Population / Denominator (d=80 patients) = 80 patients Performance Rate= Performance Met (a=40 patients) = 40 patients = 57.14% Data Completeness Numerator (70patients) = 70 patients Page 5 of 5